pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Wegovy · news · pharmadog
← back to Wegovy
News mentioning Wegovy
159
stories
Aug 11, 26
After tasting IPO success, Hemab’s CEO seeks ‘flavor of a multi-product coagulation company’
fiercebiotech
Aug 11, 26
Opinion: Burdensome Medicare GLP-1 program may keep patients from accessing $50 per month weight loss drugs
stat
Aug 7, 26
Novo Nordisk’s CFO on the oral Wegovy rollout and beyond
fiercebiotech
Aug 6, 26
Actimed gets back rights to wasting disease drug, ending $126M deal with Faraday
fiercebiotech
Aug 5, 26
Lilly confident in slow and steady Foundayo launch, as ex-US sales shine
biospace
Aug 5, 26
Lilly, FDA retatrutide biologic dispute comes to a head as submission nears
biospace
Aug 5, 26
Lilly climbs, Novo falls as obesity drug battle intensifies
biopharma dive
Aug 5, 26
Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1
biospace
Aug 5, 26
Novo CEO sees innovation as a matter of survival amid pipeline setbacks
biospace
Aug 5, 26
‘It’s been a roller coaster’: Novo Nordisk’s CFO reflects on ‘pressure’ to drive growth
fiercebiotech
Aug 5, 26
Novo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed data
fiercebiotech
Aug 4, 26
Novo dips 6% on Wegovy pill stumble despite Q2 earnings beat
biospace
Jul 31, 26
Trump administration tries again to institute rebates in 340B
biopharma dive
Jul 31, 26
Novo's IL-6 inhibitor fails in cardiovascular Phase 3, plunging shares more than 9%
biospace
Jul 31, 26
‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spree
fiercebiotech
Jul 29, 26
FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s data
biopharma dive
Jul 29, 26
Novo ordered to face CagriSema fraud claims from shareholders: New Jersey court
biospace
Jul 29, 26
Novo Nordisk fails to dismiss lawsuit over CagriSema readout
fiercebiotech
Jul 28, 26
FDA offers updated guidance for generics of weight loss blockbusters
endpoints
Jul 28, 26
Altimmune’s next-gen GLP-1 curbs heavy drinking in ‘unequivocal’ ph. 2 alcohol use disorder win
fiercebiotech
Jul 24, 26
Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma
biopharma dive
Jul 23, 26
Chutes & Ladders—Biogen R&D vet gets in Formation
fiercebiotech
Jul 23, 26
Lilly, with new data, to seek FDA approval of obesity drug retatrutide
biopharma dive
Jul 23, 26
STAT+: Pharmalittle: We’re reading about Lilly obesity drug data, a push for FDA to ban DTC ads, and more
stat
Jul 21, 26
Samsung Biologics targets $1.8B PolyPeptide buyout to expand in obesity
biospace
Jul 21, 26
Novo sues Lilly, alleging ‘misleading’ advertising of obesity drugs
biopharma dive
Jul 21, 26
STAT+: Pharmalittle: We’re reading about Novo suing Lilly over ‘deceptive’ ads, a fugitive’s secret life in biotech, and more
stat
Jul 21, 26
STAT+: Novo Nordisk sues Eli Lilly over GLP-1 drug ads it calls ‘deceptive’
stat
Jul 20, 26
Pain drugmaker Latigo outlines plans to go public
biopharma dive
Jul 20, 26
STAT+: Pharmalittle: We’re reading about a telehealth firm and patient safety, PBMs overcharging, and more
stat
← prev
page 3 of 6
next →
